Rebif

Trial finds Sanofi's teriflunomide no better than Rebif

The TENERE study compared two oral doses of teriflunomide (7mg and 14mg once daily) to standard-dose treatment with Merck KGaA Rebif brand of interferon beta, but found Sanofi's drug ... Lemtrada proved more effective than Rebif in a trial reported in

Novartis releases trial results backing Gilenya safety profile

These results also backed up two previous trials, which showed reductions in relapse rates for patients on Gilenya compared to both placebo and Merck Serono's Rebif (interferon beta-1a).

European regulators back wider indication for Merck Serono’s Rebif

It is part of our on-going commitment to improving access to Rebif for patients with this devastating disease, and supporting its appropriate use.”. ... The study, which used a human serum albumin-free formulation of Rebif, involved 517 patients.

Sanofi's Lemtrada outperforms Merck Serono's Rebif in a head-to-head trial

The CARE-MS II trial showed Lemtrada (alemtuzumab) outperforming Merck Serono's Rebif (interferon beta-1a) and meeting both of the study's primary endpoints. ... Lemtrada also met the second of its co-primary end points, cutting the risk of sustained

Positive phase III MS results from Sanofi

Data showed that treatment with alemtuzumab resulted in a 55 per cent reduction in relapse rate when compared with Rebif, and therefore met the primary endpoint. ... The second primary endpoint of time to six month sustained accumulation of disability,

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]